Complex AneuploidyESCALATENCT07227116
Evaluating the Status of Complex Aneuploidy to Locate Additional Transferrable Embryos
An observational study of Complex Aneuploidy and Chaotic Aneuploidy, run by Shady Grove Fertility Reproductive Science Center at 12 sites in 2 countries.
Trial summary
This study aims to evaluate the reproductive potential of embryos classified as "complex aneuploid" (involving three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) through preimplantation genetic testing for aneuploidy (PGT-A). Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Complex Aneuploidy, Chaotic Aneuploidy
- How many people
- 280 participants
- Where
- 12 sitesin 2 countries
- Study dates
- 1 Nov 2025to Jun 2026
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All patients with one or more embryos in storage that meet criteria for Chaotic or Complex Aneuploidy by PGT-A with NGS
Who may be able to join
- Having ≥ 1 embryo classified as whole chromosome chaotic or complex aneuploid of 3 or more chromosomes following preimplantation genetic testing for aneuploidy using an NGS based platform Signed informed consent
Who cannot join
- Embryos not meeting complex/chaotic criteria Patients declining consent
Trial locations and contacts
12 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Benjamin S Harris, MD, MPH contact
12 sites in 2 countries
United States11 sites, 11 recruiting
- Recruiting
Shady Grove Fertility
Atlanta, Georgia, 30342
Paula Morton, 3015451423, paula.morton@sgfertility.com
- Recruiting
Shady Grove Fertility
Cary, North Carolina, 27519
Vanessa Silva, 3015451423, vanessa.silva@sgfertility.com
- Recruiting
Shady Grove Fertility
Cary, North Carolina, 27519
3015451423
- Recruiting
Shady Grove Fertility
Chesterbrook, Pennsylvania, 19087
Maria Thompson, 3015451423, maria.thompson@sgfertility.com
- Recruiting
Shady Grove Fertility
Fairfax, Virginia, 22031
Kristine Milne, 3015451423, kristine.milne@sgfertility.com
- Recruiting
Fertility Center of Illinois
Highland Park, Illinois, 60035
Juergen Lieberman, 3015451423, Juergen.Liebermann@fcionline.com
3015451423
- Recruiting
IVF Florida Reproductive Associates
Margate, Florida, 33063
Kathy Miller, PhD, HCLD, 3015451423
- Recruiting
Shady Grove Fertility
Norfolk, Virginia, 23507
Caitlin Willaims, 3015451423, caitlin.williams@sgfertility.com
- Recruiting
Shady Grove Fertility
Richmond, Virginia, 23235
Daniel Graff, 3015451423, daniel.graff@sgfertility.com
9192805007, benjamin.harris@sgfertility.com
- Recruiting
Shady Grove Fertility
Rockville, Maryland, 20850
Joshua Lim, 3015451423, josh.lim@sgfertility.com
- Recruiting
Shady Grove Fertility
Towson, Maryland, 33607
Kim Arcusa, 3015451423, kim.arcusa@sgfertility.com
Chile1 site, 1 recruiting
- Recruiting
SGFertility Chile Medicina Reproductiva
Santiago, Santiago Metropolitan, 7630000
SGF Research Team SGF Research Team, (301) 545-1423, SGFClinicalResearchTeam@sgfertility.com
3015451423
About this study
Official title: ESCALATE: Evaluating the Status of Complex Aneuploidy to Locate Additional Transferrable Embryos
This study aims to evaluate the reproductive potential of embryos classified as "complex aneuploid" (involving three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) through preimplantation genetic testing for aneuploidy (PGT-A). Specifically, we seek to determine whether embryos initially reported as having multiple chromosomal abnormalities might still have the potential for normal chromosomal composition, the opportunity for transfer, and ultimately, the potential to achieve a live birth through re-biopsy and reanalysis.
Key Information:
Read more
This portion of the study seeks your consent for the re-biopsy and genetic reanalysis of the embryos only. It does not yet include consent for potential future transfer.
Participation remains completely voluntary, and your decision will not affect your current or future care.
We deeply appreciate your support and commitment to advancing fertility research.
Read the detailed description
Recently, the term "chaotic" has come into the PGT-A reporting lexicon, defined (perhaps arbitrarily) as 6 or more aneuploidies detected. Complex aneuploidy refers to embryos with multiple chromosomal aneuploidies. In one large study, complex aneuploidy at the cleavage stage was found in 41% of embryos overall, 29% of embryos in women 27-37 years old, and 45% of embryos in women 38-45 years old. By the blastocyst stage, only 10% of all embryos were complex aneuploid, with 13.7% of embryos in women aged 38-47 years compared to 4.5% in women aged 27-37 years demonstrating complex aneuploidy. Multiple aneuploidies were also detected in a retrospective study of 1502 spontaneous abortions, with 4.6% of cases showing double aneuploidy and only 0.4% showing 3 or more aneuploidies (2).
The high rate of complex aneuploidy in cleavage and blastocyst stage embryos even among young patients suggests multiple mitotic errors in the first few cell divisions, which would likely lead to developmental arrest (2). Therefore, if transferred, such embryos would be expected not to implant or to miscarry. Historically, embryos with multiple chromosomal abnormalities have therefore been de-selected for transfer or even discarded. However, recently Lin et al. reported a healthy live birth following chaotic embryo transfer (3), calling into question the assumed non-viability of chaotic embryos. Might some of these embryos correct multiple aneuploidies and become euploid? It is plausible that any euploid population of cells could have a higher survival rate and a higher mitotic rate, and if abnormal cells undergo apoptosis, a euploid embryo could result. This could explain the low rate of complex aneuploidy seen in miscarriages. An additional explanation is that imperfections in the biopsy, amplification, and/or NGS PGT-A process occasionally lead to noisy reads, that are interpreted as multiple chromosomal abnormalities, but actually reflect artifact. For such embryos, re- testing may result in euploid results.
Small studies (published in abstract form only) have evaluated the reproducibility of chaotic results from NGS-based PGT-A. A retrospective cohort study evaluated 58 'chaotic' embryos via PGT-A of re-biopsy samples. Thirty-eight percent (n=22) of embryos had euploid re-biopsy results (4). Our group reported re-biopsy of 64 embryos initially classified as chaotic and identified 17% (n=11) of embryos in the cohort as euploid and only 67% concordance between initial and re-biopsy sample results (5). Four blastocysts with euploid results on re- biopsy were transferred, resulting in two ongoing pregnancies. Furthermore, we have pooled data from multiple IVF clinics within our network that have conducted re-biopsy of embryos with multiple aneuploidies and found that overall, 22% had euploid PGT-A results on re-biopsy (Background Table, unpublished data).
In anticipation of conducting a prospective observational study to characterize the nature of PGT-A results indicating 3 or more aneuploidies, we have begun to catalog and hold these embryos in storage. To date, 112 patients with have explicitly expressed interest in contributing 128 embryos resulted as 'chaotic' or 'complex aneuploid' of 3-5 chromosomes, for the purposes of this research, and we anticipate identifying multiples of this number upon a
retrospective database search and with prospective accumulation of additional PGT-A results. Following a retrospective database search, we have identified a total of 274 'chaotic' and 5251 'complex aneuploid' embryos having been reported using NGS based PGT-A. Limited data exist on the reproductive potential of embryos classified as having multiple chromosomal abnormalities, and preliminary data, including from our center, suggest a high false positive rate. The large volume of ART performed within our network represents a unique opportunity to characterize the clinical significance of these results, in the hopes of minimizing embryo wastage and maximizing live birth from IVF cycles using PGT-A.
The aim of this study is to evaluate the reproductive potential of embryos classified as "complex aneuploid" of three or more chromosomes or "chaotic" on initial trophectoderm biopsy sample analyzed by next generation sequencing based preimplantation genetic testing for aneuploidy. We plan to do this by prospectively enrolling patients with embryos classified as such, re-biopsy of the embryos, and analysis of repeat biopsy samples. We also plan to have an independent, blinded geneticist make diagnoses, as possible, based on the NGS profiles.
- Conditions
- Complex Aneuploidy, Chaotic Aneuploidy
- Keywords
- Chaotic, Complex, Aneuploidies, Embryos
- Medical subject headings
- Aneuploidy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Multiple Aneuploidy Embryos | Embryos identified by PGT-A as having multiple chromosomal aneuploidies. DNA from trophectoderm re-biopsy samples will be retained by the testing laboratory for confirmatory analysis and quality control under IRB-approved protocols. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reproducibility
To evaluate embryos with 3 or more chromosomes deemed aneuploid with NGS-based PGT-A by performing repeat biopsy and analyzing with NGS.
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2025
- Study start1 Nov 2025 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Complex AneuploidyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 280 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Shady Grove Fertility Reproductive Science Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Benjamin Harris, Shady Grove Fertility Reproductive Science Center
- Investigators
- Kate Devine, MD, Study director, Shady Grove FertilityBenjamin S Harris, MD, MPH, Principal investigator, Shady Grove Fertility
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07227116
- Sponsor's protocol ID
- 20250101
- Acronym
- ESCALATE
- Status last verified
- Nov 2025
- First submitted
- 7 Nov 2025
- Last updated
- 12 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ESCALATE: Evaluating the Status of Complex Aneuploidy to Locate Additional Transferrable Embryos
- ClinicalTrials.gov ID
- NCT07227116
- Acronym / sponsor ID
- ESCALATE / 20250101
- Conditions
- Complex Aneuploidy, Chaotic Aneuploidy
- Keywords
- Chaotic, Complex, Aneuploidies, Embryos
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 280 participants (estimated)
- Lead sponsor
- Shady Grove Fertility Reproductive Science CenterUniversity, hospital or other
- Study start
- 1 Nov 2025 (estimated)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 12 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the reproductive potential of embryos classified as "complex aneuploid" (involving three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) through preimplantation genetic testing for aneuploidy (PGT-A). Specifically, we seek to determine whether embryos initially reported as having multiple chromosomal abnormalities might still have the potential for normal chromosomal composition, the opportunity for transfer, and ultimately, the potential to achieve a live birth through re-biopsy and reanalysis.
Key Information:
This portion of the study seeks your consent for the re-biopsy and genetic reanalysis of the embryos only. It does not yet include consent for potential future transfer.
Participation remains completely voluntary, and your decision will not affect your current or future care.
We deeply appreciate your support and commitment to advancing fertility research.
Detailed description
Recently, the term "chaotic" has come into the PGT-A reporting lexicon, defined (perhaps arbitrarily) as 6 or more aneuploidies detected. Complex aneuploidy refers to embryos with multiple chromosomal aneuploidies. In one large study, complex aneuploidy at the cleavage stage was found in 41% of embryos overall, 29% of embryos in women 27-37 years old, and 45% of embryos in women 38-45 years old. By the blastocyst stage, only 10% of all embryos were complex aneuploid, with 13.7% of embryos in women aged 38-47 years compared to 4.5% in women aged 27-37 years demonstrating complex aneuploidy. Multiple aneuploidies were also detected in a retrospective study of 1502 spontaneous abortions, with 4.6% of cases showing double aneuploidy and only 0.4% showing 3 or more aneuploidies (2).
The high rate of complex aneuploidy in cleavage and blastocyst stage embryos even among young patients suggests multiple mitotic errors in the first few cell divisions, which would likely lead to developmental arrest (2). Therefore, if transferred, such embryos would be expected not to implant or to miscarry. Historically, embryos with multiple chromosomal abnormalities have therefore been de-selected for transfer or even discarded. However, recently Lin et al. reported a healthy live birth following chaotic embryo transfer (3), calling into question the assumed non-viability of chaotic embryos. Might some of these embryos correct multiple aneuploidies and become euploid? It is plausible that any euploid population of cells could have a higher survival rate and a higher mitotic rate, and if abnormal cells undergo apoptosis, a euploid embryo could result. This could explain the low rate of complex aneuploidy seen in miscarriages. An additional explanation is that imperfections in the biopsy, amplification, and/or NGS PGT-A process occasionally lead to noisy reads, that are interpreted as multiple chromosomal abnormalities, but actually reflect artifact. For such embryos, re- testing may result in euploid results.
Small studies (published in abstract form only) have evaluated the reproducibility of chaotic results from NGS-based PGT-A. A retrospective cohort study evaluated 58 'chaotic' embryos via PGT-A of re-biopsy samples. Thirty-eight percent (n=22) of embryos had euploid re-biopsy results (4). Our group reported re-biopsy of 64 embryos initially classified as chaotic and identified 17% (n=11) of embryos in the cohort as euploid and only 67% concordance between initial and re-biopsy sample results (5). Four blastocysts with euploid results on re- biopsy were transferred, resulting in two ongoing pregnancies. Furthermore, we have pooled data from multiple IVF clinics within our network that have conducted re-biopsy of embryos with multiple aneuploidies and found that overall, 22% had euploid PGT-A results on re-biopsy (Background Table, unpublished data).
In anticipation of conducting a prospective observational study to characterize the nature of PGT-A results indicating 3 or more aneuploidies, we have begun to catalog and hold these embryos in storage. To date, 112 patients with have explicitly expressed interest in contributing 128 embryos resulted as 'chaotic' or 'complex aneuploid' of 3-5 chromosomes, for the purposes of this research, and we anticipate identifying multiples of this number upon a
retrospective database search and with prospective accumulation of additional PGT-A results. Following a retrospective database search, we have identified a total of 274 'chaotic' and 5251 'complex aneuploid' embryos having been reported using NGS based PGT-A. Limited data exist on the reproductive potential of embryos classified as having multiple chromosomal abnormalities, and preliminary data, including from our center, suggest a high false positive rate. The large volume of ART performed within our network represents a unique opportunity to characterize the clinical significance of these results, in the hopes of minimizing embryo wastage and maximizing live birth from IVF cycles using PGT-A.
The aim of this study is to evaluate the reproductive potential of embryos classified as "complex aneuploid" of three or more chromosomes or "chaotic" on initial trophectoderm biopsy sample analyzed by next generation sequencing based preimplantation genetic testing for aneuploidy. We plan to do this by prospectively enrolling patients with embryos classified as such, re-biopsy of the embryos, and analysis of repeat biopsy samples. We also plan to have an independent, blinded geneticist make diagnoses, as possible, based on the NGS profiles.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multiple Aneuploidy Embryos | – | –Embryos identified by PGT-A as having multiple chromosomal aneuploidies. DNA from trophectoderm re-biopsy samples will be retained by the testing laboratory for confirmatory analysis and quality control under IRB-approved protocols. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with one or more embryos in storage that meet criteria for Chaotic or Complex Aneuploidy by PGT-A with NGS
Key inclusion criteria (1 listed)
- Having ≥ 1 embryo classified as whole chromosome chaotic or complex aneuploid of 3 or more chromosomes following preimplantation genetic testing for aneuploidy using an NGS based platform Signed informed consent
Key exclusion criteria (1 listed)
- Embryos not meeting complex/chaotic criteria Patients declining consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Reproducibility
Time frame: one year
To evaluate embryos with 3 or more chromosomes deemed aneuploid with NGS-based PGT-A by performing repeat biopsy and analyzing with NGS.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2025.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Benjamin S Harris, MD, MPH contact
Kate Devine, MD study director
Shady Grove Fertility
Benjamin S Harris, MD, MPH principal investigator
Shady Grove Fertility
12 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Complex Aneuploidy and Chaotic Aneuploidy, run by Shady Grove Fertility Reproductive Science Center at 12 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United States, Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact SGF Research Team SGF Research Team ((301) 545-1423, SGFClinicalResearchTeam@sgfertility.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reproducibility (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2025.